$CLMT

Calumet (CLMT) insider reports latest stock dealings

Calumet, Inc. (CLMT) director reported stock transactions. On 08/20/2026, 488 shares were disposed of, and 162 restricted stock units were acquired, both at $0. The director's total beneficial ownership changed accordingly. The filing was signed by Connor J. Egan as attorney-in-fact.

Original reporting
Published Aug 21, 2026, 8:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 22, 2026, 10:23 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$CLMT
Neutral
medium confidence
Mentioned
$CLMT
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CLMTNeutralLow
01

Why it matters

The filing provides the first public disclosure of this insider transaction, offering a modest informational edge.

02

Market read

Insider RSU acquisition is a low‑impact event; traders may note it but it is unlikely to drive significant price movement.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed could make the RSU grant more meaningful.

Relevance 4/10Novelty 5/10Timing: filing disclosed on 08/21/2026, same day as transaction

Background

Calumet, Inc. (ticker CLMT) filed a Form 4 reporting a director's acquisition of restricted stock units.

Company-level read

Ticker impact

$CLMTNeutralMedium confidence
Context

Director Connor J. Egan acquired 650 restricted stock units of Calumet, Inc. on 08/20/2026, increasing his direct ownership.

Expected impact

Limited short-term impact; may marginally support price if investors view insider buying positively.

Evidence & confidence

Form 4 is a primary source, but the transaction size is small relative to market cap, reducing materiality.

Market effects

Minimal effect on the mining sector; insider activity is not a sector catalyst.

No notable regional impact.

Limited to investors tracking Calumet.

Counterpoint

The small insider purchase may be a routine compensation grant rather than a confidence signal.

Key entities

  • Calumet, Inc.

    US-listed mining company (ticker CLMT).

  • Connor J. Egan

    Director and 10% owner of Calumet, Inc.

Related articles

$CLMTMed

S&P upgrades Calumet rating to B- on stronger earnings

S&P Global Ratings upgraded Calumet Inc. to 'B-' from 'CCC+' due to stronger earnings in H1 2026 and improved credit metrics. The company's earnings grew on high margins for specialty oils and renewable fuels. S&P expects adjusted debt to EBITDA of 6x-7x in the next 12 months. Calumet redeemed $100M in senior unsecured notes in July 2026 and plans to expand sustainable aviation fuel production.

$CLMTMedAI 8/10

Calumet (CLMT) Q2 2026 Earnings Call Transcript

Calumet (CLMT) reported Q2 2026 Adjusted EBITDA with Tax Attributes of $175.2 million, driven by Specialty Products and Solutions at $161.7 million. Net loss was $95.9 million, mainly from non-cash RINs expenses of $163.6 million. The company said it repaid $115 million of debt in July, including $100 million note redemption, and discussed SAF expansion and hedges.

$CLMTMed

Why Calumet Stock Is Rocketing Higher Today

Calumet (CLMT) shares rose 15.2% to about $5.99 by 2:36 p.m. ET after a 6.8% drop the prior week. Bank of America kept a buy rating and raised its price target to $45 from $38, citing stronger free cash flow and debt retirement. Calumet reported about $54M free cash flow in Q2 2026 and retired $115M debt in July.

$CLMTMedAI 8/10

CLMT Stock Jumps As Revenue Beats And Debt Falls

Calumet Inc (NASDAQ: CLMT) shares rose about 10.56% after Q2 results and guidance. The company reported Q2 revenue of $1.45B versus a FactSet estimate of $1.12B, with EPS improving to -$1.09 from -$1.70. Operating cash flow was about $92.3M and free cash flow about $54M, alongside $115M debt reduction in July. Goldman Sachs raised its CLMT price target to $40 from $36 but kept a Neutral rating.

$CLMTMed

CLMT Stock Jumps As Revenue Beat Fuels Deleveraging Story

Calumet Inc. (CLMT) shares rose about 10.56% after the company reported Q2 revenue of $1.45B versus $1.12B expected, and narrowed its EPS loss to -$1.09 from -$1.70. The quarter included $54M free cash flow and management cited $115M debt reduction in July, alongside a MaxSAF 150 expansion at Montana Renewables.

$CLMTMed

Why Calumet Stock Flopped on Friday

Calumet (CLMT) shares fell about 6% on Friday after its Q2 earnings showed a surprise net loss. Revenue rose to just under $1.45B, up about 41% YoY, but adjusted net loss was $95.9M, or $1.09/share, versus a year-ago deficit of $147.9M. Analysts expected profit of $0.17/share. Long-term debt exceeded $2.2B.